Commentary on Keyes and Patrick: Changes in psychedelic use in the United States may require changes in our narrative of psychedelic harms

Hallucinogen use among young adults ages 19–30 in the United States: Changes from 2018 to 2021

(2023) Katherine M. Keyes et al.   ADDICTION

Australia to prescribe MDMA and psilocybin for PTSD and depression in world first

(2023) Rich Haridy   NATURE

Longitudinal and transcultural assessment of the relationship between hallucinogens, well-being, and post-traumatic growth during the COVID-19 pandemic

(2023) José Carlos Bouso et al.   Scientific Reports

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

(2022) Guy M. Goodwin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Psychedelic Drug Legislative Reform and Legalization in the US

(2022) Joshua S. Siegel et al.   JAMA Psychiatry

Trends in Ketamine Use, Exposures, and Seizures in the United States up to 2019

(2021) Joseph J. Palamar et al.   AMERICAN JOURNAL OF PUBLIC HEALTH

The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant

(2017) Ben Sessa   PSYCHOPHARMACOLOGY